Pioneering the Future of
Regenerative Therapeutics.
Led by veteran biotechnology entrepreneurs, translational molecular geneticists, and physician executives dedicated to ending avoidable amputations through first-in-class small-molecule medicine.
The Minds Behind ZegeneX
Combining decades of world-class academic research with clinical trial leadership and pharmaceutical commercial execution.
Manush Saydmohammed
Ph.D., MBA
Biotechnology entrepreneur and translational research leader with deep expertise across molecular biology, topical drug delivery formulation, and biotech venture creation. Led ZegeneX through foundational discovery, US composition-of-matter patent execution, and IND-enabling preclinical programs.
Michael Tsang
Ph.D.
Renowned developmental biologist, molecular geneticist, and Professor of Developmental Biology. Internationally recognized authority on cell signaling cascades, FGF pathways, and tissue regeneration mechanisms. Pioneer of the upstream kinase modulation pathway underlying Zegen-X5.
Marc Cordero
MD, MBA
Board-certified physician executive and clinical development strategist with extensive background across complex wound care, clinical protocol engineering, and hospital health system operations. Directs Phase I/II clinical trial design and regulatory strategy.
Rooted in Premier Academic Medicine
Born from academic research in the Pittsburgh Life Sciences Corridor, ZegeneX bridges laboratory discovery with biopharmaceutical development. Supported by prestigious non-dilutive foundation funding including the Richard King Mellon Foundation, our team is committed to translating breakthrough cellular biology into accessible bedside treatments.
Connect with Our Leadership
Whether you are an institutional investor, potential co-development partner, or scientific collaborator, our executive team welcomes your inquiries.